Revelation Biosciences, Inc. REVB
Set alert
At close · Oct 30
After hours · Oct 30, 4:57 PM ET
- YTD
- +25.94%
- 1 year
- -19.40%
- Open
- 3.79
- Prev close
- 3.74
- Mkt cap
- 2.29M
- Vol
- 22.21K
- Avg vol
- 10.54K
- EPS
- 32.20
- P/E
- 0.13
- Div yield
- 0.00%
More statistics
- Low
- 3.75
- High
- 4.03
- Forward P/E
- -0.13
- Beta
- 0.00
- Short ratio
- 0.11
- Inst. own
- 8.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 0.7149
- 200-d avg
- 1.49
- 1y target
- 12.75
News
2 weeks ago gurufocus.com
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
[url="]Revelation Biosciences, Inc.[/url] (NASDAQ: REVB) (the âCompanyâ or âRevelationâ), a clinical-stage life sciences company developing innovative s
-
2 weeks ago benzinga.com
Revelation Biosciences Announces 1-For-7 Reverse Stock Split, Effective Oct. 20
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today
2 weeks ago businesswire.com
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday's after-market session. The company's market cap stands at $19.8 million. Profusa (NASDAQ:PFSA) stock…
-
2 months ago benzinga.com
Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
– Study on track to begin later this year –Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat
2 months ago businesswire.com
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat…
-
2 months ago benzinga.com
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses…
2 months ago accessnewswire.com
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions…
-
3 months ago benzinga.com
Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available…
3 months ago accessnewswire.com
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions…
3 months ago accessnewswire.com
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
-
3 months ago benzinga.com
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced…
3 months ago accessnewswire.com
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
5 months ago accessnewswire.com
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
5 months ago accessnewswire.com
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
-
5 months ago benzinga.com
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
-
5 months ago benzinga.com
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over…
5 months ago accessnewswire.com
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 months ago accessnewswire.com
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
-
7 months ago benzinga.com
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS…
7 months ago accessnewswire.com
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS…
7 months ago accessnewswire.com
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
7 months ago accessnewswire.com
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
8 months ago defenseworld.net
Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update
Revelation Biosciences, Inc. (NASDAQ: REVB - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling…
-
8 months ago benzinga.com
Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over…
8 months ago accessnewswire.com
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
-
9 months ago benzinga.com
Revelation Biosciences Files Prospectus For The Resale Of 4,272,500 Shares Via Warrants For Potential Proceeds Up To ~$14.7M
Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 4,272,500 shares of common stock, par value $0.001 per share, by the…
-
9 months ago benzinga.com
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
-
9 months ago benzinga.com
How Do Investors Really Feel About Revelation Biosciences Inc?
How Do Investors Really Feel About Revelation Biosciences Inc?
-
9 months ago benzinga.com
Revelation Biosciences To Implement 1-For-4 Reverse Stock Split, January 28
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The…
9 months ago accessnewswire.com
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will…
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
Revelation Biosciences Enters Definitive Agreement For Immediate Exercise Of 13.065M Warrants At $0.86/Share
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive…
9 months ago accessnewswire.com
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
9 months ago benzinga.com
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED)
US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP exceeds estimates.
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
9 months ago benzinga.com
Why Ericsson Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Why Ericsson Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
9 months ago feeds.benzinga.com
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
9 months ago benzinga.com
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
9 months ago benzinga.com
Revelation Biosciences Reaches Agreement With FDA On Approval Pathway For Gemini To Treat Acute Kidney Injury
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced that the Company has reached…
9 months ago accessnewswire.com
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the…
-
9 months ago benzinga.com
Revelation Biosciences Starts GMP Production Of GEMINI, Placebo
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
11 months ago benzinga.com
Revelation Biosciences Announces The FDA Has Accepted Its End-Of-Phase 1 Meeting Package For Gemini, Its Acute Kidney Injury Treatment Candidate
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session